Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropathology ; 29(5): 597-601, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19622111

ABSTRACT

We describe a case of desmoplastic infantile ganglioglioma (DIG) in a 9-month-old boy located in the temporal lobe. Grossly the tumor was brown and superficially located. Histologically the tumor contained pigment in numerous neoplastic cells, shown to be melanosomal melanin by ultrastructural examination. Pigmented neoplasms have been reported at various sites in the central and peripheral nervous system. Previous reports on pigmented neuroepithelial tumors include neoplasms containing melanin, while others have contained neuromelanin and or lipofuscin. This case represents the first description of pigmented neoplastic cells in DIG, enlarging the spectrum of pigmented primary CNS tumors.


Subject(s)
Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Ganglioglioma/metabolism , Ganglioglioma/pathology , Melanins/metabolism , Brain Neoplasms/ultrastructure , Follow-Up Studies , Ganglioglioma/ultrastructure , Humans , Infant , Magnetic Resonance Imaging , Male , Temporal Lobe/metabolism , Temporal Lobe/pathology , Temporal Lobe/ultrastructure
2.
Eur J Endocrinol ; 155(2): 371-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16868153

ABSTRACT

OBJECTIVES: Somatostatin (SST) analogues play an important role in the medical management of somatotroph pituitary adenomas and new agonists have the potential to be effective in a wider group of pituitary and other tumours. The anti-proliferative effect of SST occurs through multiple mechanisms, one of which is cell-cycle arrest, where p27, a cyclin-dependent kinase inhibitor, is an important regulator. We hypothesised that SST may upregulate p27 protein levels and downregulate the MAP kinase pathway in these tumours. METHODS: Human pituitary adenoma cells and rat pituitary cell line (GH3) were cultured and treated in vitro with octreotide and the broad-spectrum SST agonist SOM230 (pasireotide). Immunoblotting for p27 and phospho-ERK (pERK) was performed and proliferation assessed by [3H]-thymidine incorporation. Histological samples from acromegalic patients treated with octreotide before surgery were immunostained for p27 and compared to samples from untreated patients matched for sex, age, tumour size, extension and invasiveness. RESULTS: We detected upregulation of p27 protein levels with SST analogue treatment in vitro in human pituitary adenoma samples. pERK1/2 was inhibited by SST analogues in both the human samples and GH3 cells. SST and its analogues inhibited the proliferation of GH3 cells. p27 immunostaining was stronger in samples from patients with longer preoperative octreotide treatment (more than 6 months) than in samples from patients with shorter treatment periods. CONCLUSIONS: This study demonstrates that SST-mediated growth inhibition is associated with the downregulation of pERK and upregulation of p27. More potent and broader-spectrum SST analogues are likely to play an increasing role in the treatment of tumours, where the MAP kinase pathway is overactivated.


Subject(s)
Adenoma/drug therapy , Antineoplastic Agents, Hormonal/pharmacology , Cyclin-Dependent Kinase Inhibitor p27/metabolism , MAP Kinase Signaling System/drug effects , Octreotide/pharmacology , Pituitary Neoplasms/drug therapy , Adenoma/metabolism , Animals , Cell Division/drug effects , Cell Line, Tumor , Down-Regulation/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Growth Hormone-Secreting Pituitary Adenoma/drug therapy , Growth Hormone-Secreting Pituitary Adenoma/metabolism , Humans , In Vitro Techniques , Pituitary Gland/cytology , Pituitary Neoplasms/metabolism , Prolactinoma/drug therapy , Prolactinoma/metabolism , Rats , Somatostatin/analogs & derivatives , Somatostatin/pharmacology , Thymidine/pharmacokinetics , Tritium , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...